KR101276425B1 - 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 - Google Patents

증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 Download PDF

Info

Publication number
KR101276425B1
KR101276425B1 KR1020077028059A KR20077028059A KR101276425B1 KR 101276425 B1 KR101276425 B1 KR 101276425B1 KR 1020077028059 A KR1020077028059 A KR 1020077028059A KR 20077028059 A KR20077028059 A KR 20077028059A KR 101276425 B1 KR101276425 B1 KR 101276425B1
Authority
KR
South Korea
Prior art keywords
acid
imatinib
combination
lower alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077028059A
Other languages
English (en)
Korean (ko)
Other versions
KR20080021633A (ko
Inventor
레일라 알랜드
폴 더블유. 맨리
위르겐 메스탄
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20080021633A publication Critical patent/KR20080021633A/ko
Application granted granted Critical
Publication of KR101276425B1 publication Critical patent/KR101276425B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077028059A 2005-06-03 2006-06-02 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물 Expired - Fee Related KR101276425B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68775805P 2005-06-03 2005-06-03
US60/687,758 2005-06-03
PCT/US2006/021307 WO2006132930A1 (en) 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Publications (2)

Publication Number Publication Date
KR20080021633A KR20080021633A (ko) 2008-03-07
KR101276425B1 true KR101276425B1 (ko) 2013-06-19

Family

ID=36968749

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028059A Expired - Fee Related KR101276425B1 (ko) 2005-06-03 2006-06-02 증식성 질환을 치료 또는 예방하기 위한피리미딜아미노벤즈아미드 화합물과 이마티닙의 조합물

Country Status (26)

Country Link
US (2) US7767688B2 (https=)
EP (1) EP1893213B1 (https=)
JP (2) JP5281887B2 (https=)
KR (1) KR101276425B1 (https=)
CN (1) CN101180060B (https=)
AT (1) ATE457727T1 (https=)
AU (1) AU2006255559B2 (https=)
BR (1) BRPI0611506A2 (https=)
CA (1) CA2608814C (https=)
CY (1) CY1110027T1 (https=)
DE (1) DE602006012313D1 (https=)
DK (1) DK1893213T3 (https=)
ES (1) ES2339593T3 (https=)
HR (1) HRP20100265T1 (https=)
IL (1) IL187408A0 (https=)
MA (1) MA29565B1 (https=)
MX (1) MX2007015159A (https=)
NO (1) NO20080037L (https=)
NZ (1) NZ563446A (https=)
PL (1) PL1893213T3 (https=)
PT (1) PT1893213E (https=)
RU (1) RU2430727C2 (https=)
SI (1) SI1893213T1 (https=)
TN (1) TNSN07453A1 (https=)
WO (1) WO2006132930A1 (https=)
ZA (1) ZA200709473B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006255559B2 (en) * 2005-06-03 2009-12-17 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CN102719530B (zh) * 2012-05-07 2013-11-06 厦门艾德生物医药科技有限公司 一种用于检测PDGFRα基因突变的引物、探针及试剂盒
KR101386697B1 (ko) * 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
AU2018306149B2 (en) 2017-07-26 2021-09-16 Ftf Pharma Private Limited Liquid dosage forms of imatinib
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
AU2006255559B2 (en) * 2005-06-03 2009-12-17 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases

Also Published As

Publication number Publication date
PL1893213T3 (pl) 2010-08-31
EP1893213A1 (en) 2008-03-05
RU2007147957A (ru) 2009-07-20
TNSN07453A1 (en) 2009-03-17
MA29565B1 (fr) 2008-06-02
CY1110027T1 (el) 2015-01-14
JP2013035853A (ja) 2013-02-21
MX2007015159A (es) 2008-02-15
ATE457727T1 (de) 2010-03-15
NZ563446A (en) 2011-02-25
US7767688B2 (en) 2010-08-03
AU2006255559B2 (en) 2009-12-17
IL187408A0 (en) 2011-07-31
DE602006012313D1 (de) 2010-04-01
EP1893213B1 (en) 2010-02-17
US8653093B2 (en) 2014-02-18
CN101180060A (zh) 2008-05-14
JP5281887B2 (ja) 2013-09-04
HRP20100265T1 (hr) 2010-06-30
KR20080021633A (ko) 2008-03-07
CA2608814C (en) 2013-09-03
SI1893213T1 (sl) 2010-05-31
ZA200709473B (en) 2008-12-31
US20100190800A1 (en) 2010-07-29
ES2339593T3 (es) 2010-05-21
DK1893213T3 (da) 2010-06-07
BRPI0611506A2 (pt) 2010-09-14
RU2430727C2 (ru) 2011-10-10
AU2006255559A1 (en) 2006-12-14
CA2608814A1 (en) 2006-12-14
US20080312252A1 (en) 2008-12-18
WO2006132930A1 (en) 2006-12-14
PT1893213E (pt) 2010-04-19
JP2008542390A (ja) 2008-11-27
NO20080037L (no) 2008-01-03
CN101180060B (zh) 2011-12-28
HK1115528A1 (en) 2008-12-05

Similar Documents

Publication Publication Date Title
US8653093B2 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
US20080255171A1 (en) Combination of Nilotinib with Farnesyl Transferase Inhibitors
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
EP2007391B1 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
AU2006208638B2 (en) Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
WO2007051862A1 (en) Combination of organic compounds
US20080207658A1 (en) Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
HK1115528B (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160613

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160613

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000